Impact of repeated four-monthly anthelmintic treatment on Plasmodiuminfection in preschool children: a double-blind placebo-controlled randomized trial by Patrick Kirwan et al.
RESEARCH ARTICLE Open Access
Impact of repeated four-monthly anthelmintic
treatment on Plasmodium infection in preschool
children: a double-blind placebo-controlled
randomized trial
Patrick Kirwan1*, Andrew L Jackson1, Samuel O Asaolu2, Sile F Molloy1, Titilayo C Abiona3, Marian C Bruce4,
Lisa Ranford-Cartwright4, Sandra M O’ Neill5, Celia V Holland1
Abstract
Background: Helminth infections can alter susceptibility to malaria. Studies need to determine whether or not
deworming programs can impact on Plasmodium infections in preschool children.
Methods: A double-blind placebo-controlled randomised trial was conducted to investigate the impact of
anthelmintic treatment on Plasmodium infection in children aged 12-59 months. Children were randomly assigned
to receive either albendazole or placebo every four months for 12 months with a follow-up at 14 months.
Results: 320 children (out of 1228, 26.1%) complied with all the follow-up assessments. Plasmodium prevalence
and mean Plasmodium parasite density was significantly higher in the treatment group (44.9% and 2319 ± SE 511)
compared to the placebo group (33.3% and 1471 ± 341) at baseline. The odds of having Plasmodium infection
increased over time for children in both the placebo and treatment groups, however this increase was significantly
slower for children in the treatment group (P = 0.002). By month 14, mean Plasmodium density had increased by
156% in the placebo group and 98% in the treatment group but the rate of change in Plasmodium density was
not significantly different between the groups. The change from baseline in haemoglobin had a steeper increase
among children in the treatment group when compared to the placebo group but this was not statistically
significant.
Conclusions: Repeated four-monthly anthelminthic treatments for 14 months resulted in a significantly lower
increase in the prevalence of Plasmodium infection in preschool children which coincided with a reduction in both
the prevalence and intensity of A. lumbricoides infections.
Trial Registration: Current controlled trials ISRCTN44215995
Background
Infections with multiple parasitic species are common in
nature [1]. Synergistic and competitive interactions can
occur between parasite species, which can influence the
likelihood of their successful transmission to other hosts
and increase or decrease their overall pathogenic impact
[2]. It is estimated that over a third of the world’s popu-
lation are infected with helminths [3] or one or more of
the Plasmodium species [4]. Populations infected with
helminths and Plasmodium are mainly confined to the
tropics and subtropics and this results in high rates of
co-infection [2]. It has been demonstrated that helminth
infections can impact on Plasmodium parasite densities
[5] and alter susceptibility to clinical malaria [6]. Hel-
minth-malaria interactions have been studied in animals
models [7] and humans [5,8-11]. To date human studies
investigating helminth-malaria interactions have been
carried out in older age groups with contrasting results
[12,13].
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In 2001, the World Health Assembly passed a resolu-
tion urging member states to control the morbidity of
soil transmitted helminth (STH) infections through
large-scale use of anthelminthic drugs for school-aged
children in less developed countries [14]. It has also
been recommended that preschool children should be
included in these deworming programs [15]. Given that
preschool children, defined as aged less than five years,
make up between 10%-20% of the two billion people
worldwide who are infected with STHs [3] and young
children are a high risk group for malaria [16], it
is essential to determine whether or not deworming
programs have the potential to significantly impact on
Plasmodium infections in preschool children.
The need for well-designed longitudinal intervention
studies to examine the relationship between helminths
and malaria has been acknowledged [17]. To date, two
intervention studies in the published literature have
investigated the relationship between A. lumbricoides
and malaria, both of which have included school age
children and adults [5,6]. We therefore conducted the
first double-blind placebo-controlled randomised trial to
establish the effect of repeated four-monthly anthel-
minthic treatments for 14 months on the prevalence of
Plasmodium infection and Plasmodium parasite density
in preschool children living in four semi-urban commu-
nities in Nigeria where STH prevalence is high.
We have previously reported that 50% of the pre-
school children recruited into this trial were infected by
one or more helminths, the most prevalent STH being
A. lumbricoides (47.6%), and that repeated four-monthly
treatments were successful in significantly reducing the
prevalence and intensity of A. lumbricoides infections
[18]. This paper investigates the potential impact of
anthelminthic treatment on Plasmodium infection in the
same cohort of children.
Methods
Study area and participants
The study was carried out between May 2006, and
August 2007, in four semi-urban villages, Akinlalu, Ipe-
tumodu, Moro and Edunabon, situated near Ile-Ife,
Osun State, Nigeria. The dry season extends from
November to March while the rainy season occurs from
April to October [19]. STHs and malaria are endemic in
this region [18,20]. Malaria transmission is intense,
occurring all year round, with a major peak during the
rainy season [20]. P. falciparum is the predominant spe-
cies, present in the majority (99.5%) of Plasmodial infec-
tions, while P. malariae and P. ovale are present in 17%
and 9.8% of infections respectively [21]. The study area,
participants, enrolment, study design, randomization
and sample size estimate have been previously described
[18]. Informed consent was obtained from each mother
to enroll their child. The study protocol was approved
by the Ethics and Research Committee, Obafemi Awo-
lowo University Teaching Hospitals’ Complex, Ile-Ife,
Nigeria.
Study design
The study was a double-blind placebo-controlled rando-
mised trial. Children aged 12-59 months were randomly
assigned to receive either albendazole or placebo every
four months for 12 months with a follow-up at 14
months. Children who complied with all the assess-
ments received either treatment (albendazole) or pla-
cebo tablets on four occasions. Children aged one year
received 200 mg of albendazole (1 tablet) and children
aged ≥ 2 years received 400 mg (2 tablets) of albenda-
zole [15]. Children in the placebo group were treated
with albendazole at the end of the study. This trial is
reported in accordance with the CONSORT guide-lines
for randomised studies [22].
Children were screened for STHs and Plasmodium at
baseline, 4, 8, 12, and 14 months. Stool samples were
obtained before treatment was provided and stools were
processed by formol-ether concentration [18]. To main-
tain consistency all stool samples (one per child per
time point) were examined by PK. The primary out-
comes were infection with Plasmodium spp., Plasmo-
dium density, and malaria attacks. The secondary
outcomes were haemoglobin concentration and nutri-
tional status. Finger-prick blood samples were used to
undertake a malaria rapid test and make thick and thin
blood smears for each child. Plasmodium was diagnosed
using Parascreen rapid diagnostic tests (RDTs; Zephyr
Biomedicals, Verna Industrial Estate, Verna Goa, India).
In line with local practice, on the day of the assessment,
an ‘uncomplicated’ malaria attack was defined as a posi-
tive RDT and a fever (> 37.5°C).
Children suffering a malaria attack were treated with
Coartem (artemether-lumefantrine) [23]. Data from
Parascreen RDTs are not presented in this paper. For
the purpose of analysis, malaria attacks were defined ret-
rospectively as children with a fever (> 37.5°C) who were
diagnosed with Plasmodium parasites by microscopy of
blood slides. Due to the overwhelming prevalence of P.
falciparum in this region, the infections were not further
divided into those with P. malariae or other species for
the analysis. Slides were stained with a 3% Giemsa solu-
tion [24] and examined using a × 1000 oil immersion
magnification by the Kenya Medical Research Institute
(KEMRI). Total Plasmodium density was measured by
counting the number of asexual parasites against 200
leucocytes in the thick blood film and assuming an aver-
age of 8000 leucocytes/μL of blood.
Anthropometric measurements (height and weight)
and nutritional assessments have been described
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elsewhere [18]. Haemoglobin (g/dl) was measured with a
haemoglobinometer (Accuscience, Ireland) from a finger
prick blood sample. The haemoglobinometer was cali-
brated daily prior to fieldwork. Auxillary temperature
was taken with a digital thermometer. All children
received 10 ml of oral multivitamins (over two days) as
an incentive at each time point. Each 5 ml of multivita-
min contained: Vitamin A 3000 IU, Vitamin B2 2.0 mg,
Nicotinamide 15.0 mg, Vitamin B1 1.5 mg, Vitamin B6
2.0 mg, Vitamin D2 400 IU, D panthenol 1.0 mg.
Statistical analysis
Statistical analysis was carried out in SPSS 14.01 and R
v2.6.2 [25]. Socio-economic status (SES) was calculated
as a score based on the number of key possessions (type
of toilet facilities, generator, fridge, television, radio,
mobile phone) in each child’s household. A measure of
household income was also included in the index
calculation.
Children in the treatment and placebo groups were
compared on the basis of their baseline characteristics:
age, sex, village, SES, parasitic infections and clinical
indicators (see Table 1). A similar analysis was also
undertaken to compare the characteristics of children
that were lost to follow-up and children that were
included in the analyses. Children were included in the
analyses if they complied with the four assessments and
follow up at 14 months. Statistical analyses were carried
out using Chi-squared tests for proportions (or Fisher’s
exact test when more than 20% of the cells had
expected counts <5), two-sample t-tests to test eggs per
gram (epg) and SES and Mann Whitney U tests to test
continuous variables that were non normally distributed.
To account for the difference in Plasmodium preva-
lence and Plasmodium parasite density between the treat-
ment and placebo groups at baseline, the analyses
compared the rate of change in Plasmodium prevalence,
Plasmodium parasite density and haemoglobin in the
treatment group with the rate of change in the placebo
groups. The Plasmodium prevalence data were analysed
using a linear mixed effects model using a logit function
with the assumption that the observed data were binomi-
ally distributed. The analyses were run in R v2.6.2 using
the function lmer contained in the package lme4. A ran-
dom effect for each individual was included to take
account of the nested data structure (multiple observa-
tions made on each child). The effect of treatment (treat-
ment or placebo), village and sex were included as fixed
factors, and time as a linear covariate. Data were analyzed
initially for all age groups combined (1-4 year olds at
enrolment) and then identical analyses were performed
on each separate age group (1, 2, 3 and 4 years). Para-
meter effects in the linear mixed effects models are esti-
mated on a linear scale as log(odds), their effects are
correspondingly additive with respect to their intercept,
and the presented standard errors of the estimates are
symmetrical. In order to determine the proportional
change in odds referred to in the text, we calculate exp
(log(odds)) so that the effects on the odds scale are corre-
spondingly multiplicative with respect to their intercept.
Plasmodium parasite density was measured at base-
line, 4, 8, 12 and 14 months. Plasmodium parasite den-
sity at baseline was subtracted from the densities at 4, 8,
12 and 14 months to provide a measurement for the
rate of change in malaria parasite density. Since the data
were not independent it was analysed by repeated mea-
sures rmANOVA (General Linear Model) with the dif-
ferent time points as a within-subject factor. Group,
village, age and sex were chosen as the between-subject
factors. The distribution of Plasmodium parasite density
was not normal and therefore was log-transformed for
the purposes of statistical analysis. The malaria attack
data was not analyzed because the data were sparse and
over-dispersed.
Haemoglobin concentration was measured at 0, 4, 8,
12 and 14 months from the same individuals and was
analysed using rmANOVA using the same procedure as
for the Plasmodium parasite density. The haemoglobin
measurement at baseline was subtracted from the mea-
surement at 4, 8, 12 and 14 months to provide a mea-
surement for the change in haemoglobin (g/dl) from
baseline. This was done on an individual subject basis.
The drug used to treat malaria infection was Coartem
(artemether-lumefantrine). The difference in the total
intake of Coartem, prescribed by the study doctor,
between the treatment and placebo group was tested
using a chi-squared analysis.
Results
Baseline characteristics
Of the 1228 children, 320 (26.1%) complied with all the
follow-up assessments. Figure 1 shows the trial profile.
The baseline characteristics were similar for those chil-
dren who completed the trail and those who were lost to
follow-up (Table 1), with two exceptions as follows: (i)
fewer children from Akinlalu village were lost to follow-
up than in the other three villages and (ii) children that
were lost to follow-up had a significantly higher mean
weight than children who completed the trial. Therefore
the randomized design resulted in a similar distribution
of most of the general physiological baseline variables
between the treatment and placebo groups (Table 1).
At the time of recruitment into the study, there was a
significantly higher prevalence of Plasmodium and
greater Plasmodium density in the treatment group
when compared to the placebo group, although the
infection status of the children was not known when
they were allocated into the treatment groups. In the
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linear mixed effects model analysis children in the treat-
ment group had approximately twice the odds of having
malaria than children in the placebo group (effect of
treatment, P = 0.001, Table 2). Correspondingly, mean
haemoglobin concentration was also significantly lower
in the treatment group at baseline when compared to
the placebo group.
Effect of anthelminthic treatment on Ascaris infection
The most prevalent STH amongst the children was
A. lumbricoides (Table 1). The effect of four-monthly
anthelmintic treatment on Ascaris infection has been
described in a previous publication [18]. However, for
clarity, a brief description is included here. The study
demonstrated that repeated four-monthly anthelminthic
treatment was successful in reducing prevalence and
intensity of A. lumbricoides infections in preschool chil-
dren. At the end of the follow-up period, 12% and 43%
of the children were infected with A. lumbricoides and
mean epg was 117 (S.E. 50) and 1740 (S.E. 291) in the
treatment and placebo groups respectively compared to
45% and 45% of the children infected with Ascaris and
mean epg being 1095 (S.E. 237) and 1126 (S.E. 182) in
the treatment and placebo respectively at baseline. Of
Table 1 Baseline characteristics - comparing individuals who did not fully comply and individuals who were analysed















1 314 (34.6%) 108 (33.8%) 0.137a 59 (37.3%) 49 (30.2%) 0.085a
2 202 (22.2%) 86 (26.9%) 38 (24.1%) 48 (29.6%)
3 204 (22.5%) 76 (23.8%) 31 (19.6%) 45 (27.8%)
4 188 (20.7%) 50 (15.6%) 30 (19%) 20 (12.3%)
Sex
Male 475 (52.3%) 159 (49.7) 0.419a 85 (53.8%) 74 (45.7%) 0.146a
Female 433 (47.7%) 161 (50.3) 73 (46.2%) 88 (54.3%)
Village
Akinlalu 112 (12.3%) 73 (22.8%) < 0.001a 33 (20.9%) 40 (24.7%) 0.708a
Ipetumodu 407 (44.8%) 128 (40%) 65 (41.1%) 63 (38.9%)
Moro 170 (18.7%) 49 (15.3%) 27 (17.1%) 22 (13.6%)
Edun-abon 219 (24.1%) 70 (21.9%) 33 (20.9%) 37 (22.8%)
Socio-economic status index
Mean ± SE 6.52 ± 0.11 6.29 ± 0.06 0.058b 6.49 ± 0.15 6.56 ± 0.16 0.757b
Parasitic infections
Plasmodium spp.f - - 71 (44.9%) 54 (33.3%) 0.033a
Mean parasitaemiaf - - 2319 ± 511 1471 ± 341 0.025b
Ascaris lumbricoides 439 (48.3%) 146 (45.6%) 0.402a 73 (46.2%) 73 (45.1%) 0.838a
Mean epg ± SE 1080 ± 167 1075 ± 88 0.500e 1146 ± 283 1016 ± 183 0.926b
Trichuris trichiura b 36 (4%) 10 (3.1%) 0.496a 4 (2.5%) 6 (3.7%) 0.750d
Hookwormb 40 (4.4%) 13 (4.1%) 0.795a 4 (2.5%) 9 (5.6%) 0.171a
Schistosoma haematobium b 11 (1.2%) 3 (0.9%) 1a 0 (0%) 3 (1.9%) 0.248d
Clinical indicator
Malaria attacksf - - 4 (2.5%) 4 (2.5%) 1d
Haemoglobin (g/dl; mean ± S.E.) 9.75 ± 0.05 9.69 ± 0.09 0.542b 9.54 ± 0.12 9.88 ± 0.11 0.039b
Weight (kg; mean ± S.E.) 11.98 ± 0.09 11.56 ± 0.14 0.019b 11.48 ± 0.20 11.64 ± 0.21 0.576b
Height (cm; mean ± S.E.) 88.01 ± 0.35 86.61 ± 0.51 0.064e 85.64 ± 0.87 87.02 ± 0.72 0.221b
a c2 test
b t-test
c Mean epg not given as the number of eggs detected was very low
d Fisher’s exact test
e Mann Whitney U
f Data on malaria was only available for those individuals who were analysed
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importance was the observation, that it took three
rounds of anthelmintic treatment before the prevalence
of Ascaris dropped in the treatment group. In contrast,
intensity of ascariasis dropped after one round of anthel-
mintic treatment [18].
Effect of anthelminthic treatment on Plasmodium
infection
During the study period, the prevalence of Plasmodium
infection had increased for the first 8 months of the
study for children in the treatment group and for the
first 12 months for children in the placebo group
(Figure 2A). The steepest increase in the prevalence of
Plasmodium infection in the placebo group from 8 to
12 months occurred from the dry to the wet season
while the prevalence of Plasmodium infection in the
treatment group plateaued. By 14 months, the preva-
lence of Plasmodium infection had increased by 46.5%
and 107% in the treatment and placebo groups respec-
tively when compared to the prevalence at baseline
(Figure 2A). Infection reached a plateau for both groups
(65% in the treatment group and 69% in the placebo
group) by 12-14 months after the start of the study.
The odds of having Plasmodium infection increased
over time for children in the placebo group, increasing
proportionally by 1.15 per month (Figure 3AB; Table 2,
effect of time P < 0.001). Children in the treatment
group also increased in their odds of having Plasmo-
dium infection over time (Figure 3AB), however this
increase was significantly slower than the placebo group
(Table 2, interaction between time and treatment, P =
0.002) and their odds increased by 1.08 per month
(Table 2, 1.15 × 0.94 = 1.08). A similar analysis was car-
ried out separately for each age group and all age groups
in the treatment group showed a slower increase in
Plasmodium infection although this effect did not reach
statistical significance at 95% confidence level (data not
shown).
Plasmodium density increased from baseline reaching
a plateau at 12 months in both the treatment and pla-
cebo groups (Figure 2B). By 14 months, mean Plasmo-
dium density increased by 156% (mean Plasmodium
Figure 1 Trial Profile.
Table 2 Linear mixed effects model for the prevalence of
Plasmodium spp. in children of all ages, with parameter
estimates (expressed as both odds and log-odds) and
associated standard error of the estimate (of the log-
odds coefficients) and p-values.
Coefficient Odds Log Odds
Estimate
Std. Error P-value
Intercept 0.46 -0.79 0.25 0.002
Group(treatment) 2.10 0.72 0.22 0.001
Akinlalu 1 0 - -
Ipetumodu 0.47 -0.75 0.20 < 0.001
Moro 1.10 0.05 0.25 0.83
Edunabon 0.58 -0.54 0.22 0.01
Age 1.18 0.16 0.07 0.02
Time 1.15 0.14 0.14 < 0.001
Time:Group(treatment) 0.94 -0.07 0.02 0.002
AIC value = 2027
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density at baseline of 1470 parasites per μL of blood to
3768 at 14 months) in the placebo group and by 98%
(mean Plasmodium density at baseline of 2319 to 4601
at 14 months) in the treatment group. The treatment
and placebo groups showed the same pattern in the rate
of change in Plasmodium density throughout the study
period (rmANOVA, interaction time*group (within sub-
ject analysis) F2, 558 = 0.456, P = 0.628). The rate of
change in Plasmodium density did not significantly dif-
fer between the treatment and placebo groups (main
effect of group (between subject analysis) F1, 288 = 0.025,
P = 0.874).
The prevalence of clinical malaria attacks was low
throughout the study period (Table 1) ranging from
3% at 4 months to 7% at 14 months. There was no
significant difference in the intake of Coartem
between treatment (50, 31.6%) and placebo (48, 29.6%)
groups.
Effect of anthelminthic treatment on haemoglobin level
Mean haemoglobin level remained higher in the placebo
group compared to the treatment group throughout the
study period, except at the 12 month survey point where
the haemoglobin level was similar for both groups (10.04
g/dl ± S.E. 0.11 in the treatment group and 10.03 g/dl ± S.
E. 0.11 in the placebo group; data not shown). Mean hae-
moglobin level increased by 4%, from 9.54 g/dl at baseline
to 9.94 at 14 months, in the treatment group and
increased by 2.3%, from 9.88 g/dl at baseline to 10.11 at 14
months, in the placebo group. The change in mean hae-
moglobin level varied over time, increasing from -0.209 at
4 months to 0.313 at 14 months (Table 3; rmANOVA,
main effect of time (within subject analysis) F3, 843 = 6.714,
P < 0.001). The change in haemoglobin levels increased
from 4 months to 8 months in both the treatment and pla-
cebo groups and while the change stabilized in the placebo
group it increased in the treatment group to 12 months
Figure 2 (A) Prevalence rates (Plasmodium spp.) and (B) mean malaria parasite density in treatment (solid line) and placebo (dotted
line) groups during the follow-up period. Treatment group n = 158, Placebo group n = 162.
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and decreased slightly thereafter (Figure 4). Although the
pattern in the change of haemoglobin concentration
seemed to differ between the treatment and placebo
groups this was not significant (Table 3; interaction time*-
group (within subject analysis) F3, 843 = 0.893, P = 0.445).
There was no difference in the change in haemoglobin
concentration between the treatment and placebo groups
(Table 3; main effect of group (between subjects analysis)
F1, 281 = 1.981, P = 0.160). The pattern in the change of
haemoglobin concentration significantly differed between
the villages over time (Table 3; interaction time*village
(within subject analysis) F3, 843 = 3.128, P = 0.001). Change
in haemoglobin concentration increased from 4 to 12
months in Ipetumodu and Edunabon in both the treat-
ment and placebo groups and decreased thereafter. The
pattern of change in haemoglobin was different in Akin-
lalu and Moro. In Akinlalu change in haemoglobin con-
centration in both the treatment and placebo groups
increased from 4 to 8 months, decreased from 8 to 12
months and increased thereafter (data not shown). Change
in haemoglobin concentration in Moro, in both the treat-
ment and placebo groups, decreased from 4 to 8 months,
increased from 8 to 12 months and decreased thereafter
(data not shown). There was no difference in the change
in haemoglobin concentration between the villages
(Table 3; main effect of village (between subjects analysis)
F1, 281 = 0.156, P = 0.926).
Discussion
Repeated four-monthly anthelminthic treatments for 14
months resulted in a significantly lower increase in the
Figure 3 (A) The proportion of individuals with Plasmodium spp. parasites and (B) the log odds of individuals being infected with
Plasmodium spp. parasites over time.
Table 3 Test of within- and between- subject effects from
rmANOVA analysis on the change in haemoglobin
concentration from baseline in treatment and placebo
groups over the study period.
Source Degrees of Freedom F P-value
Within-Subject Effects
Time 3 6.714 P < 0.001
Time*group 3 0.893 0.445
Time*village 9 3.128 0.001
Time*age 9 0.728 0.684
Between-Subject Effects
Group 1 1.981 0.160
Village 3 0.156 0.926
Age 3 2.189 0.089
Error 281
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prevalence of Plasmodium infection in children aged 1 to
4 years which coincided with a reduction in both the pre-
valence and intensity of A. lumbricoides infections. This
suggests that when children of this age group become
infected with Plasmodium, infection with Ascaris could
potentially influence the ability of the child’s immune
response to clear the Plasmodium infection. The immu-
nological mechanism of action that underlines helminth/
malaria interactions has been discussed and some
authors suggest that helminths can contribute to the
slow acquisition of immunity to malaria [26].
The greater increase in Plasmodium parasite density
in the placebo group further supports the evidence that
suggests that Ascaris can leave children aged 1 to 4
years less able to control Plasmodium infection although
this was not statistically significant. This potential posi-
tive impact of anthelminthic treatment on Plasmodium
infections in pre-school children contrasts with the
results of other studies investigating the relationship
between A. lumbricoides and malaria [5,6,8]. Two stu-
dies using an intervention have been undertaken in the
Comoros islands [6] and Madagascar [5]. Both studies
have included subjects with a wide age range, 2-14 yrs
and 0 - >15 yrs, respectively. In the Comoros study,
children with heavy Ascaris infections demonstrated an
increase in clinical malaria cases with anthelmintic treat-
ment. In the present study, the significant effect of
anthelmintic treatment on Plasmodium infections was
demonstrated in a group of children where the majority
(85.9%) had light Ascaris infections [18]. The Comoro
study had limitations and has been criticized for its
small sample size (112), short follow-up (20 days) and
severely malnourished study population [17].
In Madagascar, Brutus and colleagues revealed that
while there was no effect of levamisole treatment on
P. falciparum parasite density in children aged < 5 years,
subjects more than five years of age had a significant
increase in their P. falciparum parasitaemia compared
with untreated controls[5]. The small sample size
(n = 67) in the six month to four year age group may not
have been sufficient to detect an effect of anthelmintic
treatment on P. falciparum parasitaemia. Furthermore,
the prevalence of A. lumbricoides in this age group may
have been very low in comparison to these Nigerian chil-
dren considering that the prevalence in the treatment
(26.2%) and placebo (27.4%) groups was moderate at
entry into the study. Differences in acquired malaria
immunity, owing to different transmission settings, in the
Nigerian and Madagascan population may also have con-
tributed to the contrasting results.
An observational field-based, case-control study in
rural Senegal investigated the relationship between
A. lumbricoides and severe malaria [27] demonstrating
that children infected with A. lumbricoides had an
increased risk of severe malaria. This is in line with the
results of the present study which demonstrate that chil-
dren infected with A. lumbricoides are apparently less
able to control their malaria infections, albeit uncompli-
cated malaria infections. Other studies investigating the
relationship between helminths and malaria, not differ-
entiating between helminth species, have also shown
comparable results to this study [11,28].
In the present study, as expected haemoglobin levels
increased over the study period as the children increased
in age [29]. However, There was a steeper increase in
the change in haemoglobin level among children in the
Figure 4 Change in haemoglobin among the children in the treatment and placebo groups throughout the study period.
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treatment group when compared to the placebo group.
This trend corresponds with the lower increase in pre-
valence of malaria infections associated with the trans-
mission season in the treatment group. Malaria
infection is associated with a reduction in haemoglobin
levels and can frequently lead to anaemia[30], especially
in younger children and infants [31]. Despite the fact
that the trend in haemoglobin level was not statistically
significant, the observations further support the evidence
that Ascaris can leave these preschool children less able
to control their Plasmodium infections.
The study may have some potential limitations that
need to be considered when interpreting the findings.
Plasmodium prevalence and parasite densities were sig-
nificantly lower in the placebo group at baseline and
thus it could be argued that that the placebo group had
more potential for increasing Plasmodium prevalence
and parasite densities than the treatment group. How-
ever, Plasmodium prevalence was comparable in the
treatment and placebo groups at 8 months and while
prevalence increased in the placebo group from the dry
to the wet season, when malaria transmission was likely
to be low, the prevalence reached a plateau in the treat-
ment group. This trend does not support the theory
that the faster increase in Plasmodium prevalence in the
placebo group was due to differences in Plasmodium
prevalence at baseline. Participants were not randomly
selected from the community. Achieving a random sam-
ple of study participants in this field setting would prove
very difficult owing to the widely dispersed nature of
these semi-urban communities, and to the restricted age
group being studied. Nevertheless, we believe that the
moderate sample size, small age range and randomised
design may compensate for the non-random selection of
study participants. The majority of children (74%) were
lost to follow-up. This high attrition rate may be attrib-
uted to the difficulty in retaining the participation of
such young children particularly because they are not of
school-going age. School-based studies provide a better
infrastructure and can improve compliance considerably
[32]. Bias caused by such losses was probably minor
because those lost were similar with respect to impor-
tant characteristics to those that were analyzed, apart
from village and weight. Akinlalu is less widely dispersed
than the other villages and this may account for the
higher compliance shown in Akinlalu and any potential
bias owing to this was taken into account by adjusting
for village in the analyses. We do not believe that the
intake of Coartem had any effect on the results because
few treatments (98) were given during the study period
and there was no significant difference in the intake of
Coartem between the two groups. Information on
whether the children received treatment for malaria
prior to the assessments was not recorded. The
inhabitants of these semi-urban villages have poor
access to healthcare. The Primary Health Care centres
have inadequate medical supplies and the staff are often
poorly trained. Although malaria is hyperendemic in
Osun state, the authors believe that the children did not
receive appropriate treatment for malaria outside of the
study setting.
Conclusions
This study has demonstrated that the odds of having
Plasmodium infection increased over time for children
who received both treatment and placebo, however this
increase was significantly slower in the treatment group.
This observation therefore provides some evidence to
suggest that infection with A. lumbricoides leaves these
preschool children less able to control their Plasmodium
infection.
Previous research has shown that repeated two-
monthly anthelminthic treatments can have a significant
impact on Plasmodium infection [5] and the present
study suggests that longer intervals of treatment can
also have a beneficial effect. The four-monthly treat-
ments used here are also a better representation of the
delivery frequency of anthelminthics in deworming con-
trol programmes [33]. The potential impact of anthel-
minthic treatment on Plasmodium infections
demonstrated in these preschool children implies that
large-scale deworming programmes may have a protec-
tive effect on malaria morbidity in these children in this
particular setting.
Recently, the potential opportunities for combined
control of malaria and helminths have been recognised
[34]. Efforts are already underway in central Nigeria
where the distribution of insecticide-treated bed nets
has been combined with mass drug administration for
lymphatic filariasis and STHs[35]. Treating children and
adults concurrently for helminth and Plasmodium infec-
tions may be prudent as interactions may vary with hel-
minth species which is plausible as different helminths
and protozoa have synergistic and antagonistic interac-
tions[36]. The integrated management of Plasmodium
and helminth infection could avoid possible unforseen
effects of mass distribution of anthelminthic drugs on
malaria. There is still much we do not know about hel-
minth-malaria interactions. While the results of this
study provide some illumination of potential interactions
between A. lumbricoides and malaria in children aged 1-
4 years, we do not know what the outcome of these
interactions will be in populations from different geogra-
phical settings in areas of low malaria transmission. It is
crucial that this topic receives more attention, in light of
a renewed emphasis on deworming and the fact that
integrated control programs for malaria and helminths
are not yet widespread.
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